- PharmAust (PAA) releases preliminary data from its phase 1/2 trial assessing monepantel in Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS)
- Data showed that the suppression of inflammation could be responsible for slowing down MND/ALS – known to progress through neuronal inflammation
- The aim of the trial was to monitor changes in protein levels of the mTOR pathway markers p-RPS6KB1 and p-EIF4EBP1
- Cohort one results showed that MPL decreased p-RPS6KB1 levels in five of its seven participants, while six of seven participants had decreased p-EIF4EBP1 protein levels
- PAA shares ended the day up 6.67 per cent, trading at 8 cents at market close
PharmAust (PAA) has released preliminary data from its phase 1/2 trial assessing lead drug candidate monepantel (MPL) in Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS).
Preliminary data indicated that the suppression of inflammation could be responsible for slowing down MND/ALS, which is known to progress through neuronal inflammation.
The aim of the trial was to monitor changes in protein levels of the mTOR pathway markers p-RPS6KB1 and p-EIF4EBP1.
For this trial, cohort one results showed that MPL decreased p-RPS6KB1 levels in five of its seven participants, while six of seven participants had decreased p-EIF4EBP1 protein levels.
Peripheral blood mononuclear cells (PBMCs) from the blood of all seven trial subjects were sent for analysis at the Florey Institute of Neuroscience and Mental Health in Melbourne.
The company plans to explore these possibilities with the ongoing analysis of cohort two data.
PAA shares ended the day up 6.67 per cent, trading at 8 cents at market close.